NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60722-5011-01 | 60722-5011 | PREDNISOLONE | PREDNISOLONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 2024 | In Use | |
50090-2804-00 | 50090-2804 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 20, 2017 | Oct 31, 2019 | In Use |
72789-0393-10 | 72789-0393 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 25, 2024 | In Use | |
83090-0009-10 | 83090-0009 | Arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 9, 2023 | In Use | |
59651-0488-01 | 59651-0488 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 28, 2022 | In Use | |
50090-2804-02 | 50090-2804 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 9, 2018 | Oct 31, 2019 | In Use |
59676-0040-28 | 59676-0040 | Erdafitinib | BALVERSA | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | Apr 12, 2019 | In Use | |
00069-1318-10 | 00069-1318 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Nov 9, 2020 | In Use | ||
00074-0576-22 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Apr 11, 2016 | In Use | |
72205-0061-01 | 72205-0061 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
72205-0062-01 | 72205-0062 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
72237-0101-01 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
00009-0280-02 | 00009-0280 | Methylprednisolone Acetate | Depo-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | May 28, 1959 | In Use | |
59746-0001-03 | 59746-0001 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 31, 1997 | In Use | |
72237-0101-05 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
72237-0101-06 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jun 22, 2020 | In Use | |
72237-0101-07 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jun 22, 2020 | In Use | |
00009-0306-02 | 00009-0306 | Methylprednisolone Acetate | Depo-Medrol | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | May 28, 1959 | In Use | |
00085-1425-02 | 00085-1425 | Temozolomide | Temodar | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
00085-1430-02 | 00085-1430 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | May 29, 2015 | In Use |
63759-3032-01 | 63759-3032 | Bortezomib | Bortezomib | 3.5 mg/1.4mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Sep 25, 2024 | In Use | |
00078-0180-61 | 00078-0180 | Octreotide Acetate | Sandostatin | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 13, 2012 | In Use | ||
00173-0915-61 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 27, 2023 | In Use | |
00310-3512-95 | 00310-3512 | Acalabrutinib | CALQUENCE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Aug 4, 2022 | In Use | |
00310-0512-95 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Apr 1, 2020 | Jul 31, 2025 | In Use |
Found 11120 results — Export these results